Clinical Trial Update: NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

ClinicalTrials.gov update for the Phase 3 study NBI-1065845-MDD3026 evaluating NBI-1065845 as an adjunctive treatment in major depressive disorder; the trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• NBI-1065845

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Major Depressive Disorder | Phase 3 | Status: RECRUITING